FCM
CRSP icon

Frontier Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Frontier Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-53,277
Closed -$2.88M – 289
2024
Q2 		$2.88M Sell
53,277
-48,821
-48% -$2.82M 0.03% 263
2024
Q1 		$6.96M Sell
102,098
-152,874
-60% -$10.9M 0.07% 234
2023
Q4 		$16M Sell
254,972
-10,163
-4% -$562K 0.16% 176
2023
Q3 		$12M Sell
265,135
-110,653
-29% -$5.71M 0.13% 180
2023
Q2 		$21.1M Buy
375,788
+329,441
+711% +$18.7M 0.2% 152
2023
Q1 		$2.1M Sell
46,347
-9,524
-17% -$463K 0.02% 249
2022
Q4 		$2.27M Sell
55,871
-263,039
-82% -$14M 0.02% 249
2022
Q3 		$20.8M Buy
318,910
+150,425
+89% +$10.9M 0.24% 143
2022
Q2 		$10.2M Buy
168,485
+20,568
+14% +$1.21M 0.12% 204
2022
Q1 		$9.29M Buy
+147,917
New +$9.29M 0.08% 217
2021
Q1 		– Sell
-3,186
Closed -$488K – 282
2020
Q4 		$488K Sell
3,186
-1
-0% -$118 ﹤0.01% 282
2020
Q3 		$267K Sell
3,187
-156,271
-98% -$13.9M ﹤0.01% 290
2020
Q2 		$11.7M Buy
159,458
+44,346
+39% +$2.59M 0.1% 202
2020
Q1 		$4.88M Buy
115,112
+38,476
+50% +$1.99M 0.05% 236
2019
Q4 		$4.67M Buy
+76,636
New +$4.18M 0.03% 253
2018
Q3 		– Sell
-54,631
Closed -$3.21M – 292
2018
Q2 		$3.21M Buy
+54,631
New +$3.11M 0.02% 278

Other funds holding CRSP

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Frontier Capital Management's CRSP Position: Q3 2024 in Review

Frontier Capital Management sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 53,277 shares — an estimated $2.88M sold.

Frontier Capital Management first reported a position in CRSP in Q2 2018 and held it in 16 quarters. The position peaked at $21.1M in Q2 2023. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

  • Frontier Capital Management reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Frontier Capital Management sold 53,277 CRISPR Therapeutics shares in Q3 2024, an estimated $2.88M.
  • Frontier Capital Management first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 16 quarters.
  • Frontier Capital Management's CRISPR Therapeutics position peaked at $21.1M in Q2 2023.
  • 416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on Frontier Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.